Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation.
about
Improving cell-based therapies by nanomodificationDendritic-cell-based technology landscape: Insights from patents and citation networksSialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responsesSilencing B7-H1 enhances the anti-tumor effect of bladder cancer antigen-loaded dendritic cell vaccine in vitro.Mesenchymal stem cells as a novel vaccine platform.Engineered dendritic cells for gastrointestinal tumor immunotherapy: opportunities in translational research.Transdermal immunization: biological framework and translational perspectives.Paracrine release of IL-2 and anti-CTLA-4 enhances the ability of artificial polymer antigen-presenting cells to expand antigen-specific T cells and inhibit tumor growth in a mouse model.Internalization routes of cell-penetrating melanoma antigen peptides into human dendritic cells.Nanoengineered strategies for siRNA delivery: from target assessment to cancer therapeutic efficacy.Potent anti-prostate cancer immune response induced by dendritic cells transduced with recombinant adenoviruses encoding 4-1BBL combined with cytokine-induced killer cells.Induction of antigen-specific immune responses by dendritic cells transduced with a recombinant lentiviral vector encoding MAGE-A3 gene.Assessment of tumor antigen-loaded solid lipid nanoparticles as an efficient delivery system for dendritic cell engineering.Antitumor Efficacy of Human Monocyte-Derived Dendritic Cells: Comparing Effects of two Monocyte Isolation Methods.Skin Allografting Activates Anti-tumor Immunity and Suppresses Growth of Colon Cancer in Mice.
P2860
Q28080427-26A1555F-A83A-4D0C-9F76-AF0A75905826Q28087687-FEB532FA-19EC-4464-B5E7-EEF226A1916DQ30367426-BF9F0EE2-039F-4490-AC6F-3A6CFC4AE11DQ34028415-21ACE36C-6244-4BA5-BACD-E3CBEA24BF58Q36404011-707E61CB-B729-40A7-A70E-BF955C3585DFQ38051671-31F5D49F-718C-4C55-BED3-6E8527520E28Q38068975-176B6739-B13E-417F-A6D1-DFA5573DA23DQ38684217-8027058D-2502-49C5-B331-6A7ED3841007Q39039132-C66B6B0B-FB96-4262-AE13-7982AE964754Q39066848-B72FD344-7C99-42D4-AE39-9DE5B302F7BDQ42175389-4E3FD609-5CE5-4095-BA0E-CC4F17687014Q42250138-BEE5407F-A683-4DE0-9FC9-796E8B7181B2Q43425908-2F1D7457-C5AE-401F-8392-F604CF71F1DCQ50054694-1A273636-1CA7-4BE9-A5C0-EFC2BCF4924EQ55717021-E2EE899A-AFAD-442F-87F2-B469FFBD7AF9
P2860
Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation.
@en
type
label
Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation.
@en
prefLabel
Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation.
@en
P2093
P2860
P356
P1433
P1476
Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation.
@en
P2093
Arpit Bhargava
Dinesh Mishra
Pradyumna Kumar Mishra
Smita Banerjee
P2860
P304
P356
10.2217/IMT.12.40
P577
2012-07-01T00:00:00Z